PA
NAMS icon

Perceptive Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Perceptive Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
+500,000
New +$16.5M 0.25% 67

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Perceptive Advisors's NAMS Position: Q2 2024 in Review

Perceptive Advisors sold out of NewAmsterdam Pharma (NAMS) in Q2 2024, closing a stake of 175,000 shares — an estimated $4.14M sold.

Perceptive Advisors first reported a position in NAMS in Q1 2024 and held it in 1 quarter. The position peaked at $4.14M in Q1 2024. 90 funds tracked by Wall St. Rank hold NAMS as of Q2 2024.

  • Perceptive Advisors reported no remaining NewAmsterdam Pharma position as of Q2 2024 after selling out during the quarter.
  • Perceptive Advisors sold 175,000 NewAmsterdam Pharma shares in Q2 2024, an estimated $4.14M.
  • Perceptive Advisors first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 1 quarter.
  • Perceptive Advisors's NewAmsterdam Pharma position peaked at $4.14M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.